NCT01473056View on ClinicalTrials.gov

Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

September 30, 2011

Conditions
Hepatitis C Virus Infection, Response to Therapy of
Interventions
DRUG

JTK-853

Tablets, twice a day for 3 days

DRUG

Dose 2 JTK-853

Tablets, twice a day for 3 days

DRUG

Dose 3 JTK-853

Tablets, three times a day for 3 days

DRUG

Dose 4 JTK-853

Tablets, twice a day for 3 days

DRUG

Placebo

Tablets, twice a day or three times a day for 3 days

Trial Locations (1)

00927

Fundacion de Investigacion de Diego, San Juan

Sponsors

Lead Sponsor

Akros Pharma Inc.
All Listed Sponsors
lead

Akros Pharma Inc.

INDUSTRY

NCT01473056 - Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects | Biotech Hunter | Biotech Hunter